Program
nerandomilast
Also written as “BI 1015550”, “Nerandomilast” and “Nerandomilast formulation 1”.
Its studies are mostly in Lung Diseases, Interstitial · Idiopathic Pulmonary Fibrosis · Myositis · Scleroderma, Systemic · Amyotrophic Lateral Sclerosis, led by 2 companies.
Drug pageNerandomilast: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 347 open or running | phase 3since Apr 4, 2022 | May 7, 2012 | Apr 15, 2027phase 3 · NCT06806592 |
| Gipfel Life Sciences | 11 open or running | phase 3since Jan 2, 2026 | Jan 2, 2026 | Jun 30, 2027phase 3 · NCT07321860 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gipfel Life Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 6, 2023Named nerandomilastINNProposed as its International Nonproprietary Name in WHO's List 129 · before, BI 1015550
- Jan 2, 2026First study: phase 3 study in Amyotrophic Lateral SclerosisFirst studyNCT07321860 · 60 planned
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Amyotrophic Lateral SclerosisNCT07321860
TargetBeta
“Meanwhile, nerandomilast, a selective PDE4B inhibitor, elevates intracellular cAMP in immune and glial cells, shifting pro-inflammatory signaling toward resolution and antagonizing secondary fibrotic and inflammatory cascades.”study text, by rule · the study
Other programs on PDE4B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Roflumilastrule | AstraZeneca | phase 4 | 61 |
| apremilastrule | Amgen | phase 4 | 48 |
| ensifentrinerule | Merck | phase 3 | 17 |
| difamilastrule | Otsuka | phase 3 | 16 |
| tanimilastrule | Chiesi Farmaceutici | phase 3 | 15 |
Studies
The one study Gipfel Life Sciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07321860Amyotrophic Lateral Sclerosis | 3 | Not yet recruiting | Jun 30, 2027 | 60 |
How it is read
Names in the registry
- “BI 1015550”, 27 entries
- “Nerandomilast”, 10 entries
- “Nerandomilast formulation 1”, 1 entry
- “Nerandomilast formulation 2”, 1 entry
- “Nerandomilast 18 mg - adult formulation”, 1 entry
Conditions, from the studies’ own filings
- Lung Diseases, Interstitial, 5 studies
- Idiopathic Pulmonary Fibrosis, 5 studies
- Myositis, 1 study
- Scleroderma, Systemic, 1 study
- Amyotrophic Lateral Sclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.